Related Experiment Videos
Serum complement activation of SLE patients during plasmapheresis
13rd Department of Internal Medicine, University Medical School of Debrecen, Hungary.
Autoimmunity
|January 1, 1997
Summary
The erythrocyte complement receptor 1 (ECR1) assay shows reduced immune complex binding in systemic lupus erythematosus (SLE) patients. Plasmapheresis improved ECR1 binding, suggesting its utility in monitoring SLE treatment.
Area of Science:
- Immunology
- Clinical Medicine
Background:
- Complement activation plays a role in systemic lupus erythematosus (SLE) pathogenesis.
- Erythrocyte complement receptor 1 (ECR1) is involved in immune complex clearance.
- Assays measuring ECR1-immune complex binding can assess complement system function.
Purpose of the Study:
- To evaluate the erythrocyte complement receptor 1 (ECR1)-immune complex binding assay's utility in systemic lupus erythematosus (SLE).
- To investigate the effect of plasmapheresis on ECR1-immune complex binding in SLE patients.
Main Methods:
- Utilized the erythrocyte complement receptor 1 (ECR1)-immune complex binding assay.
- Formed immune complexes using bovine serum albumin (BSA)-anti-BSA in the presence of patient serum.
- Compared binding in SLE patients versus normal volunteers and monitored changes during plasmapheresis.
Main Results:
- SLE patients exhibited lower ECR1-immune complex binding compared to normal volunteers.
- Plasmapheresis in SLE patients homozygous for the CR1/E high density allele showed beneficial effects on ECR1 binding.
- An inverse correlation was observed between serum immune complex levels and ECR1 binding in SLE patients.
Conclusions:
- The ECR1-immune complex binding assay is a sensitive tool for assessing complement activation in SLE.
- This functional assay may be valuable for monitoring plasmapheresis efficacy in SLE patients.
- ECR1 binding reflects complement activation status and immune complex levels in SLE.